Global Bio Simulation Market

In 2021, the global bio-simulation market is estimated to be USD 1.5 billion. It is expected to grow at a compound annual growth rate of 16% during the forecast period 2022-2030. The increase in recurrence cases due to the acquired drug resistance of diseases such as cancer, tuberculosis and other bacterial infections is one of the main trends stimulating market growth. This is believed to have promoted the clinical urgency of incorporating biosimulation into the initial development of a new generation of drugs.Biological simulations promote continued efforts to better understand the mechanisms of resistance and help identify therapies with high potency and lower resistance. The existence of long-term treatment, such as in the case of diabetes, can lead to poor patient compliance and the formation of resistant bacterial strains.

This will make the overall treatment plan difficult, which creates a need for biological simulation. In addition, the clinical urgency of developing advanced and highly effective drugs is expected to play a key role in market growth. Biological simulations are increasingly used for the simulation modeling of diabetes. It is used in conjunction with proteomics and genomics technology to develop models of advanced therapies.

Technological innovation and regular software updates are expected to encourage researchers to conduct biological simulations. This may provide a significant boost to the market. These technological advances include the use of microarrays and predictive models, such as top-down, bottom-up methods, hybrid models, and biochemical pathways to build models. Other advancements include semantic technology that supports a limited number of biological simulation elements, reducing the time, cost, and complexity of the entire process.

PRODUCT INFORMATION:

Software occupied a dominant share of the market in 2015. The dominant share can be attributed to the availability of a wide range of specific application software tailored to the interests and needs of researchers. For example, Rhenovia Pharma provides software that specifically simulates the mechanism of specific central nervous system drugs. Software is also increasingly being incorporated into applications such as defense, food, and aviation.

The service sector is expected to witness the highest compound annual growth rate during the forecast period. The growth of this market segment can be attributed to increasingly complex and multi-level drug development systems, in which bio-simulation services may be essential.

It is expected that this will be achieved through the development of more precise new combination therapies. Major participants are heavily involved in providing a wide range of services, which simplifies the entire biological simulation process. These services reduce overall costs, and therefore become the first choice for doctors and researchers.

APPLICATION INSIGHT:

Drug development accounted for the largest share in 2020, exceeding 60%. More and more government initiatives have promoted the integration of advanced software, driving the growth of this market segment. For example, the 2004 FDA Critical Path Initiative report emphasized the importance of this approach to drug development and recommended its integration as an effective predictive tool.

END USE INFORMATION:

In 2020, pharmaceutical and biotechnology companies accounted for a considerable share of more than 56% in the bio-simulation market. The strong demand for bio-simulation by these companies can be attributed to the continuous efforts of key companies to extend the life cycle to discover generic drugs and drug variants through computer modeling methods. For example, Rhenovia Pharma Ltd. uses computer models to determine better treatments for bipolar disorder, depression, schizophrenia, and Alzheimer's disease. It is expected that RRO will develop at an astonishing compound annual growth rate during the forecast period. Companies are increasingly inclined to reduce total spending, which is expected to intensify the growth of this segment. Other benefits mainly include higher productivity and greater focus on core development areas that are critical to the company's growth.

REGIONAL INSIGHT:

In 2020, North America was at the forefront of market growth, accounting for more than half of general market revenue. More and more key players are collaborating to improve drug discovery capabilities and are helping the market gain tremendous momentum. In addition, the use of the in-silico model during the application of regulatory policies to ensure patient safety and high standards of treatment further promoted North American participation. Due to the increasing preference for contract research organizations, the increase in healthcare IT spending, and the steady improvement of healthcare infrastructure, the Asia-Pacific region may experience exponential growth during the forecast period. In addition, the booming R&D activities of emerging economies are expected to bring huge growth opportunities to the region.

BIO SIMULATION MARKET SHARE OUTLOOK:

Major players in this field include Dassault Systemes SA; Certara USA; Advanced Chemical Development Corporation; Schrödinger Corporation; Gene Data Corporation; and Rhenovia Pharma Ltd. These participants have implemented a competitive sustainable development strategy, including product development and expansion of geographic presence in order to obtain a larger market share. Market leaders are keen to solve unmet needs and provide economic value through consistent product updates. For example, in August 2016, Certara USA, Inc. released a new version of PK/PD Phoenix 7.0 software, which improved efficiency and power. This launch is due to the importance and increasing inclusion of bio-simulation software in drug development.

MARKET SEGMENTS COVERED BY THE REPORT:

This report forecasts revenue growth at the global, regional, and country levels, and analyzes the latest industry trends in each sub-segment from 2022 to 2030. For the purpose of this research, Grand View Research has segmented the global biosimulation market report based on products, applications, end-uses, and regions: Product Outlook (Revenue, USD Million, 2022 to 2030) Software Services Internal Service Contract Service Application Outlook (revenue, millions of dollars, 2022 to 2030) drug development, drug discovery, other end-uses (revenue, millions of dollars, 2022 to 2030), pharmaceutical and biotechnology companies, CRO, regulatory agencies, academic research institutions.

"

Geography Analysis:

The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

• North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
• Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
• Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys  & Opportunity Outlook
• Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
• Middle East and Africa  (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook

.